ANDA 204744, held by Lannett. Paroxetine Hydrochloride.
As of Nov 21, 2026, ANDA 204744 (Paroxetine Hydrochloride), held by Lannett, was first approved by FDA on Jun 10, 2016, with 0 approved supplements and 0 published complete response letters.
Paroxetine is indicated in adults for the treatment of: Major depressive disorder (MDD) Panic disorder (PD) Social anxiety disorder (SAD) Premenstrual dysphoric disorder (PMDD) Paroxetine is a selective serotonin reuptake inhibitor (SSRI) indicated in adults for the treatment of: Major Depressive Disorder (MDD) Panic Disorder (PD) Social Anxiety Disorder (SAD) Premenstrual Dysphoric Disorder (PMDD)
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 10, 2016 | Original application | Approved | None posted |
| Paroxetine HydrochlorideEQ 12.5MG BASE · tablet, extended release;oral | Paroxetine Hydrochloride | Rx |
| Paroxetine HydrochlorideEQ 25MG BASE · tablet, extended release;oral | Paroxetine Hydrochloride | Rx |
| Paroxetine HydrochlorideEQ 37.5MG BASE · tablet, extended release;oral | Paroxetine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters